The stock has a 36-month beta value of -0.08. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PMN is 23.03M, and at present, short sellers hold a 0.61% of that float. On July 03, 2025, the average trading volume of PMN was 44.03K shares.
PMN) stock’s latest price update
ProMIS Neurosciences Inc (NASDAQ: PMN)’s stock price has plunge by -8.34%relation to previous closing price of $0.49. Nevertheless, the company has seen a -7.63% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-17 that CAMBRIDGE, Massachusetts, June 17, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative diseases such as Alzheimer’s Disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), as well as other misfolded protein diseases, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference today, June 17th, 2025 at 7:00 a.m.
PMN’s Market Performance
ProMIS Neurosciences Inc (PMN) has experienced a -7.63% fall in stock performance for the past week, with a -10.40% drop in the past month, and a -40.65% drop in the past quarter. The volatility ratio for the week is 4.23%, and the volatility levels for the past 30 days are at 7.64% for PMN. The simple moving average for the past 20 days is -9.25% for PMN’s stock, with a -45.61% simple moving average for the past 200 days.
PMN Trading at -14.59% from the 50-Day Moving Average
After a stumble in the market that brought PMN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.10% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PMN starting from Cashman Neil, who purchase 15,000 shares at the price of $0.97 back on Feb 10 ’25. After this action, Cashman Neil now owns 16,617 shares of ProMIS Neurosciences Inc, valued at $14,595 using the latest closing price.
Shafmaster Madge K., the Director of ProMIS Neurosciences Inc, purchase 70,000 shares at $1.30 during a trade that took place back on Sep 24 ’24, which means that Shafmaster Madge K. is holding 208,333 shares at $91,028 based on the most recent closing price.
Stock Fundamentals for PMN
The total capital return value is set at -2.15. Equity return is now at value -19.56, with -10.86 for asset returns.
Currently, EBITDA for the company is -16.83 billion with net debt to EBITDA at 8.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.36.
Conclusion
To sum up, ProMIS Neurosciences Inc (PMN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
